MedTrace Logo

SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults

NCT02492958 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2018-07-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of a single dose of Staphylococcus aureus 4 antigen vaccine in Japanese adults aged 20 to \<86 years.

Conditions

  • Staphylococcal Infections

Interventions

BIOLOGICAL

Staphylococcus aureus 4-antigen vaccine

a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm

BIOLOGICAL

Placebo

a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02492958 on ClinicalTrials.gov